Principal Financial Group Inc. Sells 2,279 Shares of Elevance Health, Inc. $ELV

Principal Financial Group Inc. trimmed its position in Elevance Health, Inc. (NYSE:ELV) by 0.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 257,145 shares of the company’s stock after selling 2,279 shares during the quarter. Principal Financial Group Inc. owned about 0.12% of Elevance Health worth $90,142,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in ELV. Sei Investments Co. increased its holdings in shares of Elevance Health by 7.7% in the second quarter. Sei Investments Co. now owns 163,668 shares of the company’s stock worth $63,666,000 after purchasing an additional 11,745 shares during the last quarter. Glenview Trust co increased its holdings in shares of Elevance Health by 41.5% in the second quarter. Glenview Trust co now owns 1,619 shares of the company’s stock worth $630,000 after purchasing an additional 475 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its holdings in shares of Elevance Health by 6.9% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 65,945 shares of the company’s stock worth $25,650,000 after purchasing an additional 4,272 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Elevance Health by 5.0% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 42,371 shares of the company’s stock worth $16,478,000 after purchasing an additional 2,012 shares during the last quarter. Finally, Quantinno Capital Management LP increased its holdings in shares of Elevance Health by 111.8% in the second quarter. Quantinno Capital Management LP now owns 43,911 shares of the company’s stock worth $17,080,000 after purchasing an additional 23,180 shares during the last quarter. 89.24% of the stock is owned by institutional investors.

Elevance Health Trading Up 1.6%

Shares of NYSE ELV opened at $374.84 on Thursday. The business’s 50 day moving average is $312.00 and its two-hundred day moving average is $331.96. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $424.24. The stock has a market capitalization of $81.40 billion, a P/E ratio of 15.94, a PEG ratio of 2.10 and a beta of 0.66.

Elevance Health (NYSE:ELV) last issued its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, topping the consensus estimate of $10.74 by $1.84. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The company had revenue of $49.49 billion for the quarter, compared to analysts’ expectations of $48.21 billion. During the same period in the previous year, the firm posted $11.97 earnings per share. The firm’s revenue for the quarter was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, research analysts expect that Elevance Health, Inc. will post 26.79 EPS for the current year.

Elevance Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be issued a $1.72 dividend. This represents a $6.88 annualized dividend and a dividend yield of 1.8%. The ex-dividend date is Wednesday, June 10th. Elevance Health’s dividend payout ratio is presently 29.26%.

Analyst Ratings Changes

ELV has been the topic of several research reports. Truist Financial reduced their target price on Elevance Health from $390.00 to $375.00 and set a “buy” rating on the stock in a report on Monday, April 13th. Robert W. Baird lifted their price target on Elevance Health from $317.00 to $331.00 and gave the stock a “neutral” rating in a research report on Thursday, April 23rd. JPMorgan Chase & Co. boosted their price objective on Elevance Health from $397.00 to $411.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 28th. Evercore boosted their price objective on Elevance Health from $345.00 to $360.00 in a research note on Thursday, April 23rd. Finally, Sanford C. Bernstein boosted their price objective on Elevance Health from $384.00 to $424.00 and gave the stock an “outperform” rating in a research note on Friday, April 24th. Thirteen equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $384.58.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.